BioNTech SE
BNTX · NASDAQ
Financial statements
Annual and quarterly income, balance-sheet, cash-flow and key-statistics data.
Income statement
| Period | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2022 FY | 17.31B | 14.32B | 12.64B | 9.43B | 38.08 |
| 2023 FY | 3.82B | 3.22B | 690.40M | 930.30M | 3.87 |
| 2024 FY | 2.75B | 2.21B | -1.31B | -665.30M | -2.77 |
| 2025 FY | 2.76B | 2.14B | -623.87M | -1.09B | -4.51 |
Balance sheet
| Period | Total assets | Liabilities | Cash | Debt | Equity |
|---|---|---|---|---|---|
| 2022 FY | 23.28B | 3.22B | 13.88B | 212.20M | 20.06B |
| 2023 FY | 23.01B | 2.76B | 11.66B | 219.10M | 20.25B |
| 2024 FY | 22.53B | 3.12B | 9.76B | 254.20M | 19.41B |
| 2025 FY | 21.98B | 2.76B | 7.67B | 267.29M | 19.22B |
Cash flow
| Period | Operating cash flow | Capital expenditure | Free cash flow | Dividends paid | Net cash change |
|---|---|---|---|---|---|
| 2022 FY | 13.58B | -363.30M | 13.21B | -484.30M | 12.18B |
| 2023 FY | 5.37B | -705.50M | 4.67B | — | -2.21B |
| 2024 FY | 207.70M | -452.30M | -244.60M | — | -1.90B |
| 2025 FY | 438.00M | -168.19M | 269.81M | — | -931.17M |
Key statistics
| Period | Market cap | Enterprise value | P/E | Price / sales | Debt / equity |
|---|---|---|---|---|---|
| 2022 FY | 34.13B | 20.47B | — | — | — |
| 2023 FY | 22.97B | 11.53B | — | — | — |
| 2024 FY | 26.45B | 16.95B | — | — | — |
| 2025 FY | 19.58B | 12.18B | — | — | — |
| 2026-12-31 | — | — | — | — | — |
| 2027-12-31 | — | — | — | — | — |
| 2028-12-31 | — | — | — | — | — |
Income statement
| Period | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2025 Q2 | 260.80M | 184.40M | -501.10M | -386.60M | -1.60 |
| 2025 Q3 | 1.52B | 1.37B | -46.90M | -28.70M | -0.12 |
| 2025 Q4 | 898.89M | 568.72M | -230.62M | -302.14M | -1.23 |
| 2026 Q1 | 120.04M | -75.83M | -671.97M | -540.65M | -2.14 |
Balance sheet
| Period | Total assets | Liabilities | Cash | Debt | Equity |
|---|---|---|---|---|---|
| 2025 Q2 | 21.64B | 3.13B | 10.27B | 269.60M | 18.51B |
| 2025 Q3 | 21.34B | 2.86B | 10.09B | 245.40M | 18.48B |
| 2025 Q4 | 21.98B | 2.76B | 7.67B | 267.29M | 19.22B |
| 2026 Q1 | 21.10B | 2.38B | 9.95B | 303.12M | 18.72B |
Cash flow
| Period | Operating cash flow | Capital expenditure | Free cash flow | Dividends paid | Net cash change |
|---|---|---|---|---|---|
| 2025 Q2 | 132.14M | 567.90M | 700.04M | — | 1.05B |
| 2025 Q3 | 854.59M | -43.45M | 811.14M | — | -195.70M |
| 2025 Q4 | 299.18M | -61.52M | 237.67M | — | -2.42B |
| 2026 Q1 | -427.92M | -57.73M | -485.66M | — | 2.12B |
Key statistics
| Period | Market cap | Enterprise value | P/E | Price / sales | Debt / equity |
|---|---|---|---|---|---|
| 2025 Q2 | 21.83B | 11.83B | — | — | — |
| 2025 Q3 | 20.10B | 10.25B | — | — | — |
| 2025 Q4 | 19.86B | 12.46B | — | — | — |
| 2026 Q1 | 19.44B | 9.80B | — | — | — |
| 2026-06-30 | — | — | — | — | — |
| 2026-09-30 | — | — | — | — | — |
| 2026-12-31 | — | — | — | — | — |